GLYCOMIMETICS INC

For the period ended Dec 31, 2024. Filed Feb 13, 2025.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2024 · Filed Feb 13, 2025

CBIO$13.65+0.8%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Statements of Cash Flows


· · Year Ended December 31,
· · 2024 · · 2023 ·
Operating activities · · · · ·
Net loss	$(37,879,158)	$(36,899,420)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation	35,174	153,301
Loss on disposal of property and equipment	46,654	8,627
Asset impairment	365,179	—
Non-cash lease expense	402,649	856,238
Issuance of common stock for services	75,375	36,000
Stock-based compensation	4,697,546	3,524,476
Changes in assets and liabilities:
Prepaid expenses and other assets	1,678,948	846,182
Prepaid research and development expenses	603,737	(553,737)
Accounts payable	(538,811)	(102,076)
Accrued expenses	156,187	(1,766,449)
Lease liabilities	(741,558)	(983,045)
Net cash used in operating activities	(31,098,078)	(34,879,903)

Investing activities
Purchases of property and equipment	(9,972)	(21,394)
Proceeds from sales of property and equipment	30,000	—
Net cash provided by (used in) investing activities	20,028	(21,394)

Financing activities
Proceeds from issuance of common stock, net of issuance costs	—	28,707,011
Proceeds from exercise of stock options	5,398	116,497
Net cash provided by financing activities	5,398	28,823,508
Net change in cash and cash equivalents	(31,072,652)	(6,077,789)
Cash and cash equivalents, beginning of period	41,792,830	47,870,619
Cash and cash equivalents, end of period	$10,720,178	$41,792,830

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.